Thymosin Alpha-1

Thymosin Alpha-1 (Tα1, thymalfasin) is a 28-amino-acid endogenous thymic peptide with immunomodulatory activity that primarily influences T-cell function, dendritic-cell activation, cytokine balance, and restoration of immune homeostasis [source:3,source:16,source:24,source:26]. It is an injectable peptide used clinically or investigationally across infections, sepsis, cancer, and immune-dysregulation states, usually as an adjunct rather than stand-alone therapy [source:3,source:4,source:8,source:9].

Thymosin Alpha-1 acts by licensing dendritic cells, particularly via Toll-like receptor 7 (TLR7) signaling after binding apoptotic bodies. This enhances antigen presentation, drives T-cell maturation, and restores immune balance [source:1,source:12,source:15]. In lymphopenic states, it promotes CD4+ and CD8+ T-cell recovery and reduces markers of T-cell exhaustion like PD-1 and Tim-3 Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. It can also shift macrophages away from tumor-promoting M2 phenotypes and lower immunosuppressive cell populations [source:12,source:15,source:27].

In a phase III sepsis trial, adjunct Thymosin Alpha-1 improved organ dysfunction scores and increased ICU-free days without increasing serious toxicity The Reset-α Study: A Double Blind, Randomized, Multi Centre, Phase III Trial for the Efficacy and Safety of Thymosin α-1 (Tα1) in Sepsis Patients. Meta-analyses in severe acute pancreatitis report higher CD4+ cells, reduced C-reactive protein, and lower extrapancreatic infection risk Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis. In unresectable hepatocellular carcinoma, retrospective data showed adding it to lenvatinib plus sintilimab improved overall survival (16 vs 11 months) and progression-free survival The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study. In advanced refractory solid tumors, the PRaG regimen with personalized Thymosin Alpha-1 produced objective responses around 24–31% with no grade ≥3 adverse events [source:1,source:2]. For viral illness, COVID-19 data are mixed: one study associated it with reduced mortality in severe lymphopenic patients Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells, while another found higher non-recovery rates after adjustment Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study. Evidence in recurrent implantation failure suggests improved implantation and pregnancy rates but is limited to small self-controlled studies [source:21,source:22].

Research protocols typically administer Thymosin Alpha-1 subcutaneously in fixed 1.6 mg to 3.2 mg doses [source:1,source:9,source:13]. In sepsis, intensive twice-daily dosing for 7 days has been studied The Reset-α Study: A Double Blind, Randomized, Multi Centre, Phase III Trial for the Efficacy and Safety of Thymosin α-1 (Tα1) in Sepsis Patients. For viral illness, daily 1.6 mg for 15 days has been reported Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by Restoration of Lymphocytopenia and Reversion of Exhausted T Cells. In oncology, a loading phase followed by maintenance dosing three times weekly is used in radioimmunotherapy regimens [source:1,source:2]. For chronic immune support, protocols with 1.6 mg twice weekly for 6–12 weeks are supported by practitioner consensus. The optimal duration remains indication-specific, with no established cycle for all uses.

Thymosin Alpha-1 is supplied as a lyophilized powder requiring reconstitution. Bacteriostatic water is commonly used to allow multi-dose use; sterile water may be used for single-dose applications. Gently swirl the vial to dissolve; avoid shaking. Store lyophilized vials refrigerated (2–8°C) or frozen (-20°C) for long-term. After reconstitution, keep solution refrigerated (2–8°C) and protect from light. Typical beyond-use dating is 14–28 days with bacteriostatic water, or 24–72 hours with sterile water. Do not freeze reconstituted solution. For travel, use a cool pack. An interactive calculator on this page can assist with dosing concentrations for specific protocols.

Thymosin Alpha-1 may synergize with immune checkpoint inhibitors, IL-15, GM-CSF, and radiotherapy, but combination increases immune overactivation risk; a case report documented multisystem toxicity with sintilimab [source:4,source:8]. It is generally compatible with antiviral and anti-infective agents. Corticosteroids and other broad immunosuppressants may blunt its immune-stimulating effects The efficacy and safety of thymosin alpha-1 combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a retrospective study. No direct peptide-peptide interactions are established, but caution is advised when stacking multiple immune-active peptides. Clinical monitoring of liver, pulmonary, and inflammatory markers is recommended when used with immunotherapies The Reset-α Study: A Double Blind, Randomized, Multi Centre, Phase III Trial for the Efficacy and Safety of Thymosin α-1 (Tα1) in Sepsis Patients.

Thymosin Alpha-1 has been studied in combination with IL-15 to reduce senescent hepatic CD8+ T cells in liver cancer models IL‐15 Plus Thymosin α1 Reduces Senescent Hepatic CD8 ⁺ T Cells in Hepatocellular Carcinoma via PI3K/AKT Suppression. It is used in PRaG regimens with PD-1 inhibitors, radiotherapy, and GM-CSF in advanced solid tumors [source:1,source:2]. In sepsis, combining it with ulinastatin showed improved outcomes in network meta-analyses Comparative efficacy and safety of immunomodulatory therapies for sepsis: a systematic review and network meta-analysis. Stacking with BPC-157 or TB-500 has no direct research data but is considered mechanistically non-overlapping. Caution is warranted when combining with other strong immunomodulators to avoid excessive immune stimulation A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1.

Thymosin Alpha-1 is not FDA-approved in the United States and is considered a research peptide in that jurisdiction. It has established clinical use in other countries, notably China, where expert consensus guidelines support its use in infectious diseases and critical care [source:3,source:26]. In sports, it is not explicitly listed by WADA, but as an immunomodulatory peptide, it may fall under broad anti-doping rules; athletes should verify current status with their sport authority. Personal importation is subject to local regulations.

Thymosin Alpha-1 is generally well tolerated, with clinical trials showing no increase in serious adverse events versus placebo [source:1,source:4]. Common side effects include injection-site reactions and mild flu-like symptoms. Immune overstimulation is a theoretical risk, particularly when combined with checkpoint inhibitors; one case report described multisystem immune-related toxicity with sintilimab A Case Report of a Multisystemic Immune-Related Adverse Event Caused by Sintilimab in Combination With Thymosin Alpha-1. It is contraindicated in patients with prior hypersensitivity and should be used with caution in autoimmune disease or organ transplant recipients. Routine monitoring of blood cell counts and inflammatory markers is advised.